Despite improvements in treatment of localized prostate cancer, local recurrence remains a significant problem. A total of 46 patients with proven local cancer recurrence following external beam radiotherapy entered a prospective clinical trial using ultrasound-guided cryosurgery to ablate the residual prostate gland. Persistent complications included one urethra-rectal fistula, incontinence (2), retention (3), and treatment induced erectile dysfunction (7). Using the PSA definitions for biochemical failure as PSA X0.3 ng/ml, the Kaplan-Meier plots showed the incidence of patients to be free of biochemical recurrence at 51 and 44% at 1 and 2 y, respectively. For a PSA X1.0, the values at 1 and 2 y were 72 and 58%.
Introduction
Prostate cancer was diagnosed in approximately 200 000 men in the United States in 2002, 1 and resulted in approximately 32 000 deaths. 2 Most men with newly diagnosed cancer have localized disease and external beam radiation therapy is a frequently used treatment for clinically localized prostate cancer. 3 In fact, the advent of technological advances, such as ultrasound guidance, have facilitated a more precise and accurate volume distribution of the radiation. Advances in imaging and computer enhancement for external beam radiation are now widely utilized, and the increasing popularity of brachytherapy has led to an overall increased use of radiation therapy. 1 As a result of this increased attractiveness of radiation therapy, approximately 50 000 patients in the United States each year receive primary radiation treatment for prostate cancer. 4 Unfortunately, 25-71% of men will fail radiotherapy, many with isolated local recurrence. [5] [6] [7] [8] [9] The treatment options for locally recurrent disease following radical radiotherapy are limited: salvage surgery which has a high risk of significant and frequent morbidity, and hormone therapy which is noncurative. [10] [11] [12] [13] Recently, cryosurgery has been advanced as an option for localized recurrence after radiotherapy based upon its successful application as a primary treatment for localized prostate cancer. [14] [15] [16] However, early results have been mixed and there have been some reports of a high frequency of severe complications in this population, particularly incontinence. 17 The purpose of this study was to prospectively evaluate the complication rates and biochemical recurrence rates following cryosurgical ablation of the prostate (CSAP) for patients with local recurrence after radical external beam radiation therapy.
Materials and methods

Patient selection
Between January 1998 and April 2002, 46 patients were enrolled and treated in this prospective Phase II clinical trial. The protocol was approved by the Office of Medical Bioethics, University of Calgary. All patients provided written informed consent.
All patients had completed external beam radiotherapy at least 12 months prior to assessment. Eligibility criteria included a histologically confirmed recurrence in the prostate gland and/or seminal vesicle (SV), PSA p20 ng/ml, and no evidence of metastatic disease on chest X-ray (CXR) or bone scan. Other evaluations were electively undertaken depending upon clinical indication and included Prostascint scan, and MRI or CT of abdomen and pelvis. The pretreatment biopsies consisted of a minimum of six cores following a transrectal ultrasound (TRUS)-guided standard sextant biopsy protocol. Additional cores were taken if disease was suspected in the SVs or locally beyond the capsule on the basis of DRE or sonographic evaluation, or if a nodule was visible during the TRUS evaluation.
The extent of local disease was determined by the findings from the biopsies and the highest gleason score was recorded. T2B disease was defined as two or more unilateral positive biopsies. T2C disease was defined as bilateral positive biopsies. T3A disease was defined as neurovascular stroma or extra-capsular involvement. T3C disease was defined as a pathologically documented invasion of the SVs.
Patients with a gland volume X60 cm 3 (determined by TRUS) were excluded. Seven patients with prostate gland volume measured by TRUS to be 30-60 g received hormonal treatment consisting of a GnRH agonist combined with an antiandrogen for approximately 3 months prior to CSAP. Antiandrogen hormonal therapy was not restarted following CSAP unless disease progression had been established.
Cryosurgery procedure
The procedure was always performed by an operating team consisting of an interventional radiologist (JS) and a urologist (BD). The cryosurgical technique used was originally described by Onik et al, which utilizes multiple cryoprobes and TRUS guidance (Figure 1) . 18 Six patients underwent a further modification of the procedure using multiple (X10) 17-gauge micro-cryoprobes, as compared to the conventional 3 mm (11 Fr.) probes.
Patients were admitted to the hospital the morning of their procedure and received intravenous antibiotics preoperatively. They remained on oral antibiotics for 2 weeks or until the suprapubic (SP) catheter was removed, which ever was longer. All patients were positioned in the Lithotomy position and a 12 Fr. pigtail SP catheter was inserted percutaneously into the bladder under flexible cystoscope monitoring from the bladder. A protective urethral warming catheter was placed in the urethra up to the bladder over a guide wire and its position confirmed by ultrasound. Throughout the cryogenic procedure, warm saline (at 40-421C) was circulated at 450-500 ml/min through the closed urethral warmer system to protect the prostatic urethra against severe freezing.
All procedures were performed with an argon-based cryogenic system. In 40/46 cases, a conventional cryogenic technique using 6-8 standard cryoprobes was used [CRYOCaret Surgical System machine (Endocare, Irvine, CA, USA) and CRYO-HITt machine (Galil Medical, Boston, USA)]. For six consecutive cases, a SeedNett machine (Galil Medical, Boston, USA) with 17 gauge micro-cryoprobes was used. In these cases, the cryoprobes were placed using a preinsertion Brachystandt (Barzell-Whitmore Inc.) and a Brachysteppert guide template (Barzell-Whitmore Inc.) under TRUS guidance. The cryoprobes were placed in an overlapping arrangement to achieve both an adequate radius and length of freezing.
In all cases, CSAP was guided and continuously monitored by TRUS with the intent of whole gland ablation. A transrectal biplane ultrasound probe was used with a 7.5 MHz linear array and 5.0 MHz transverse sector scanning crystal (Aloka, model SSD 2000, Tokyo, Japan). Thermosensor needles were placed at the neurovascular bundle regions and at the prostate apex to ensure further that the gland was adequately frozen without injury to the rectal mucosa. The thermal objective was to achieve a temperature of À401C on each freeze cycle. In no case was a temperature of warmer than À201C accepted unless there was risk of serious rectal injury from continued freezing.
The procedure consisted of two freeze cycles, with complete passive thawing of the gland between the freeze cycles. A urethral warmer was left in place with Complications were assessed by the study physicians and by utilization of standardized 'self-reporting' questionnaires completed by patients. The complications were then classified into a category, toxicity, and grade using the common toxicity criteria (CTC) in order for easier analysis and comparison of data. Additionally, operations or procedures directly related to the CSAP were recorded and presented in Table 3 . MRI was performed before and after surgery on all patients ( Figure 2 ).
Results
Participant characteristics
A summary of the characteristics of the 46 participants is presented in Table 1 . The participants ranged in age from 56 to 78 y (mean age ¼ 68.9 y). The mean PSA at admission was 5.6 ng/ml (range 0.1-16.1). The Gleason score ranged from 6 to 9 with a median value of 7 and a Figure 2 Postoperative gadolinium-DTPA enhanced axial magnetic resonance image demonstrating complete avascular necrosis of gland (signal void), with extension of the cryoablation field into surrounding periprostatic tissues as far as the muscular side wall (arrows). Preservation of periurethral tissue, which was protected by the urethral warmer can be seen at the gland center (arrow heads). Figure 3 shows patients free of biological recurrence, with PSA greater than 0.3 and 1.0 ng/ml. Four patients developed a PSA 44.0 ng/ ml, one had a negative biopsy, bone scan, pelvis MRI, Prostacinct study 19 (In-111 labeled Copramab Pendetide, Cytogen Corp., Princeton, NJ, USA) and has had no other treatment. Three patients began hormone treatment on the basis of a rapidly rising PSA: one had two sets of TRUS-guided biopsies that were negative for any cancer or viable residual prostate tissue.
Complications
There were no deaths or life threatening events as a direct result of the procedure. The major direct complications included one urethra-rectal fistula, persistent incontinence (two), and urinary retention requiring TURP (three) ( Tables 2 and 3 ). Erectile dysfunction was acutely universal although 37 of the 46 patients were unable to have erections sufficient for intercourse on enrollment.
Urethra-rectal fistula is a rare major complication experienced by patients undergoing salvage cryosurgery. 20 Our solitary patient who did experience this complication was engaged in homosexual activity, which is a reported risk factor for fistula occurrence even without prior radiation or cryosurgery. 21 All patients experienced acute transient retention as a result of prostate edema requiring SP bladder diversion. The average SP duration was 15 days (range 1-67 days), and three patients suffered from prolonged retention requiring a TURP to excise necrotic or obstructive tissue. One responded well to TURP but the other two patients developed total incontinence following the intervention (secondary incontinence). Transient incontinence and bladder discomfort are frequent in the postoperative period as the patients begin to void after withdrawal of the SP tube but patients typically recover urinary control quickly (within weeks) with only conservative care.
Persistent incontinence followed directly from cryosurgery in three patients. One recovered continence following a cystoscopy for removal of necrotic tissue from the prostate bed. Another patient was given a prosthetic sphincter 20 months following CSAP, which ultimately failed leaving the patient totally incontinent at 50 months.
At enrollment, 9/46 of the patients had intact erectile function; 4/46 were sexually active with the use of aids; while the remaining 33 men reported erectile dysfunction; and one described himself as 'sexually inactive'. All of the 13 initially sexually active patients were inactive immediately following the procedure. Seven patients showed recovery by 6 months: five were sexually active with the use of aids (three utilized PDE-5 inhibitors, two required intracavernous injections) and two regained erectile functioning.
In all, 44 of the 46 procedures were followed with a 1-day hospital convalescence. Two participants were held in hospital for 2 days primarily due to lack of home support. The prospective self-reported quality-of-life assessment will provide more information with respect 
Discussion
Cancer recurrence after radiotherapy has variously been reported to be 25-71%. [5] [6] [7] [8] [9] This broad range of recurrence rates is postulated to reflect patient selection criteria, the meticulousness with which the follow-up monitoring and biopsy was performed and variations in radiotherapy techniques applied. Risk factors for failure of radiation therapy have been identified, and include relative radioresistance of the prostatic carcinoma, failure to administer a cytotoxic dose to the entire gland, and limitations in the ability to increase dosing due to the potential of injuring surrounding tissue. 1 Suspicion of cancer recurrence following radiation treatment can manifest in several ways. Clinically, it may present with signs and symptoms of bladder outlet obstruction or upper tract obstruction. In the past decade, the most widely used method for detecting the potential of radiation failure is rising PSA levels or failure to achieve a significant PSA nadir. 1 Research on conservative management of localized prostate cancer indicates that patients with well-differentiated or moderately differentiated prostate cancer exhibit an 87% 10-year disease-specific survival rate when managed with non-curative therapy alone. 22 In contrast to this is recurrent prostate cancer, which represents a more aggressive disease variant that eventually results in cancer-related death, with a median survival of only 33 months, if left untreated. 23 Of patients with postradiotherapy prostate recurrence, 24.3% reoccur locally, 52.2% distantly, and 23.5% occur both locally and distantly. 24 Therefore, approximately half of all patients who present with evidence of radiation therapy failure (typically identified by a rising PSA) will have tumor found by a TRUS-guided prostate biopsy and half of those with a positive biopsy will be potentially curable by a local radical procedure. As a corollary, patients with local recurrence after radiotherapy harbor a substantial chance of silent synchronous distal disease.
It remains very difficult to identify which patients with a positive prostate biopsy have recurrence limited to the prostate gland. In an effort to focus aggressive local therapies to those most likely to benefit, PSA has been identified as a potential surrogate marker and those with PSA greater then 20 ng/ml are at a high risk of extensive disease. 24 Patients suspected of having persistent prostate cancer should undergo an ultrasound-guided prostate needle biopsy. Although there is a lack of consensus on the best approach, the use of 10 biopsies has been proposed, including six systematic sector biopsies in the parasaggital plane and two additional biopsies extended extremely laterally in the gland to sample the anterior horn region. 1 Additionally, an SV biopsy on each side is recommended for pathological staging. In radiorecurrent cancer, SV involvement is much higher than in the nonradiated patient. 25 A metastatic workup consisting of a bone scan and CXR is mandatory if salvage treatment is to be considered. Prostascint scans, MRI, and CT have not proven efficacious for routine application, although these tests can be performed on an individual basis if clinical suspicion dictates. Consequently, the ultimate efficacy of most salvage therapies is limited by the absence of efficacious and affordable diagnostic tools to identify early metastases. We assume that up to half of our patients who are thought to be free of metastases by conventional assessment and who undergo salvage cryotherapy may fail treatment because of synchronous metastases. Considering this reality, our study goal was both to assess the complication risk for salvage cryosurgery and to determine practical rates of biochemical salvage.
Patients with recurrent local cancer after radiotherapy have limited therapeutic options. Patients with radiation failure cannot receive additional external beam radiation to the pelvis because maximal normal tissue tolerance will have been reached during the initial treatment, and because the tumor has been proven to be radioresistant. Androgen deprivation therapy (ADT) consists of the reduction of circulating serum androgens (principally testosterone) either by surgical or medical castration and is applied in some cases. ADT may have some advantage in the ability to treat micrometastases, but many patients fail to respond to hormonal therapy, and in those who do respond, hormone-resistant disease generally develops after a median time of 18 months. 26 ADT therapy is a practical option but is not curative, provides only for an interval of disease-free status before progression continues, and is usually reserved for advanced or disseminated disease. 12 Prolonged treatment with ADT results in impotence and loss of libido, and can cause symptomatic gynecomastia and/or hot flashes, loss of muscle mass, and osteoporosis. 27 Despite the limitations of ADT, it is a commonly used treatment for local recurrence after radiation therapy because many of the patients it is used with are not candidates for salvage radical surgery. ADT may play a role in patients who have failed salvage treatment. Possibly curative radical salvage therapies include prostatectomy, cryosurgery, and, most recently, brachytherapy.
Salvage radical prostatectomy can achieve a biochemical success (PSA undetectable) rate of up to 65% at 60 months. However, salvage radical surgery is considered one of the most technically difficult procedures in urology because of the complicating effect of radiation on the surrounding tissue. Radiation results in vascular occlusion with resulting tissue hypoxia, while alterations in basement membrane proteins lead to increased fibrosis. The anatomical planes between pelvic organs is often obliterated, with a poorly vascularized bladder and urethra available for surgical reconstruction. As a result, salvage radical surgery is associated with substantial morbidity, 27 and patients receiving primary radiation therapy often exhibit too many comorbid conditions to be candidates for radical surgery to begin with. 28 Salvage cryoablation offers several advantages over salvage radical surgery, including no need for blood transfusion, brief hospitalization (average of 1 day), and shorter operation time.
Brachytherapy is a new alternative but there is limited supporting work for this and no long-term Salvage cryosurgery of the prostate BJ Donnelly et al demonstration of efficacy or safety. Moreover, preliminary analysis of brachytherapy as a salvage treatment following failed external beam radiation therapy, while still evolving, has not been promising. 29 Poor PSA outcomes along with the significant morbidity have led to questions about the benefit of salvage brachytherapy for radiation failure patients. 29 Cryosurgery has emerged as a potential salvage procedure based on its success as a primary treatment. 14, 15, 30 The innovation of real-time TRUS for monitoring, new cryogenic technologies, the development of a urethral warming device, and thermosensor monitoring has been shown to limit morbidity and improve results. 31 Additionally, several venders now offer commercial cryogenic systems that use physical principles with high-pressure room temperature gases to achieve extreme cold (Joule-Thompson effect) rather than circulating liquid nitrogen (Figure 4) .
Original clinical investigations of CSAP were carried out in the 1960s and 1970s. 32 CSAP was attempted with a single transurethral probe and achieved biochemical control equivalent to radical surgery but had an unacceptable frequency of complications, including prostatourethral, urethrocutaneous, and urethrorectal fistulas, urethral sloughing and incontinence. 20 Subsequently, open suprapubic or transperineal approaches were attempted but were limited because of the inability to monitor the progression and extent of freezing. As a result, tissue ablation was erratic, leading to either incomplete tumor ablation or unintended injury to benign tissues resulting in clinical complications. Cryosurgery was re-introduced as a primary treatment in 1989 by the radiology/urology team of Drs Onik and Cohen after their extensive modifications of the procedure to a more efficacious and safer procedure. [14] [15] [16] 33 The trend of higher rates of morbidity in earlier series can likely be attributed to the lack of availability of thermocouples, the banning by the Food and Drug Administration of early urethral warmers, and the use of nitrogen-based cryogenic systems. Optimal surgical technique for cryoablation treatment of prostate cancer has recently been described, 34 and includes the use of two freeze/thaw cycles, FDA approved urethral warming devices, thermocouple monitoring, achieving temperatures of À401C or less, and six to eight cryoprobes per procedure. Improvement of outcome in recent series can likely be attributed to these refinements in surgical methods.
In addition to incorporating the advances in the technique summarized above, there are other practical considerations that are unique to performing salvage CSAP. The prostate gland may be adherent to the anterior rectal wall as a result of the previous radiation, diminishing the thickness of Denonvilliers' fascia. An assessment of this anatomic region needs to be performed with TRUS prior to cryoablation, to determine how to place the posterior cryoprobes and the Denonvilliers thermocouple appropriately. The use of androgen deprivation therapy has been advocated, in order to decrease the overall gland size and increase the space between the anterior rectal wall and the posterior prostate capsule. This provides the cryosurgeon a few additional millimeters of working space below the gland. 25 The injection of 30-50 ml sterile saline into the space between the rectum and the prostate has been successfully used, 28 in order to expand the region to facilitate an aggressive freeze posteriorly. The hyperemia and edema induced by the saline in the rectal wall facilitate a more extensive freeze posteriorly, allowing the surgeon to shape the iceball to the shape of the anterior rectal wall.
Thermocouples are an integral component because the sole use of ultrasound monitoring is an unreliable indicator of adequate freezing. As the iceball approaches the rectal wall, DRE can be an important monitoring tool, as it allows the operator to palpate the anterior rectal wall to ensure that the mucosa feels soft over the hard iceball. 28 An additional measure to increase the safety of salvage cryoablation is the placement of a thermocouple device in the external sphincter with the aid of flexible cystoscopy. The use of an external sphincter temperature probe has been reported to reduce the incidence of urinary incontinence. The rate of urethral sloughing can likewise be reduced by leaving the urethral warming device in place for an additional period of 30-120 min following the procedure. 25 The operator should continue the freeze process for a longer duration than they might believe necessary, in order to achieve a thorough freeze. As long as the rectum is safe, it is recommended that the operator achieve an iceball that becomes distinctly flat or concave to palpation by DRE, as it expands laterally.
PSA is a well-established surrogate marker for prostate cancer follow-up and a significantly rising PSA after radical prostatectomy or radiotherapy is correlated with subsequent clinical failure in most cases. A very low or undetectable PSA nadir is widely believed to offer an effective indicator of the removal of all significant PSAproducing tissue within several weeks following definitive treatment for localized prostate cancer. Biochemical disease-free survival is considered to be a more sensitive indicator of treatment response than clinical disease-free survival, 35 and the results from prostatectomy, radiation therapy, and brachytherapy treatment of prostate cancer consistently show that PSA is the strongest predictor of disease-free survival. 36 An undetectable PSA value is highly correlated with a negative biopsy and clinically disease-free status. 37, 38 Several reports suggest the same pattern for cryotherapy.
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Figure 4 An argon gas centered cryogenic system (Endocare Inc., Irvine, CA, USA) and high-pressure argon gas tanks. 10, 11 but possible patient selection bias and our relatively short-term follow-up compromises our results. Nonetheless, these results show that patients who fail radiotherapy with limited local recurrence can achieve biochemical disease-free status and that this appears stable in the long term. Moreover, the number of patients achieving this status represents close to the theoretical number of those who will have limited local recurrence without distant metastases.
There are several prognostic factors that should be considered when selecting a patient for CSAP after failed radiation therapy. Based on other recent studies, a PSA greater than 10 ng/ml, [40] [41] [42] a high Gleason score before or after radiotherapy, [41] [42] [43] stage T3/T4 disease, 41 and a higher grade of cancer 44 all predict unfavorable outcomes. In addition to evidence of metastatic disease, patients with a prior history of transurethral resection of the prostate (TURP) should be excluded from salvage cryoablation due to the heightened risk of sloughing and urinary retention. 25 Yet, several of our patients with poor prognostic indicators have done well with persistently undetectable PSA following the procedure and we urge flexibility in applying eligibility criteria.
Cryosurgery offers incidental benefits that motivate further evaluation in its application as a salvage ablative procedure: a very short hospital stay and relatively low cost. It is also repeatable after initial failure without great concern for added complication. There is the ability, as well, to extend the freezing margin to a much broader field than with a usual surgical margin and we have done this in our patients with known T3C disease. With salvage radical surgery, unlike salvage cryoablation, extraprostatic extension at the time of surgery is a poor prognostic factor. 26 Since there is no surgical incision, blood loss and pain are minimized. 12 Finally, there is, to date, no evidence of delayed complication.
Cryotherapy can achieve biochemical success with undetectable, or very low, PSA values that remain stable at 24-36 months in many patients. This suggests that the majority of those who have only local recurrence after radiotherapy may achieve biochemical success from salvage cryotherapy. Moreover, our study particularly challenges prior reports of very frequent and serious complications and demonstrates rates of incontinence and other serious morbidity to be only marginally more so than when cryotherapy is applied as a primary therapy. There are few attractive alternatives for the care of this population who are at high risk of complication from invasive procedures, yet, with few notable exceptions, our patients did not suffer from significant compromise of lifestyle. Our study shows the safety and efficacy of cryotherapy as a salvage procedure following local cancer recurrence after radiotherapy and supports its continued application. We will continue to monitor our patients for their long-term outcome.
